Metabolite Identification Studies
The FDA guidance for Safety Testing of Drug Metabolites recommends that the structure of any metabolite which may represent more than 10 % of the exposure in humans should be formally elucidated. The earlier a disproportionate metabolite is recognized and characterised in the drug development process, the lower the risk of downstream delays with better planning of clinical studies.
The expertise and experience, in conjunction with state-of-the-art technology, are available within Arcinova to advise on the optimal approaches for completion of metabolite isolation and identification. Where possible, isolation can be circumvented by hyphenated technologies. The in-house mass spectrometry – Nuclear Magnetic Resonance platform not only enables identification of metabolites, but it permits quantification within a biological matrix.
Bio2Business 2018Bio2Business Basel 2018 will be attended by Nathalie Huther, Business Development Manager Europe.
Bio2Business 2018Dates: 19th - 20th JuneLocation: Basel, Switzerland
ChemSpec EuropeThe ChemSpec Europe Conference will be attended by Gareth Jenkins, Chief Scientific Officer at Arcinova. Gareth has been invited to chair 'Sessions 3 and 5' for the Royal Society of Chemistry's Special Symposium, during the two-day event.
ChemSpec EuropeDates: 20th - 21st June 2018Location: Cologne, Germany
Scale-up of Chemical Processes ConferenceThe Scale-up of Chemical Processes Conference will be attended by Nathalie Huther, Business Development Manager Europe.
Scale-up of Chemical Processes ConferenceDates: 25th - 27th JuneLocation: Prague